Last reviewed · How we verify
Trichloroisocyanuric Acid — Competitive Intelligence Brief
phase 2
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Trichloroisocyanuric Acid (SYMCLOSENE). Trichloroisocyanuric Acid works by releasing chlorine gas when it comes into contact with water, which then kills bacteria and other microorganisms.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trichloroisocyanuric Acid TARGET | SYMCLOSENE | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trichloroisocyanuric Acid CI watch — RSS
- Trichloroisocyanuric Acid CI watch — Atom
- Trichloroisocyanuric Acid CI watch — JSON
- Trichloroisocyanuric Acid alone — RSS
Cite this brief
Drug Landscape (2026). Trichloroisocyanuric Acid — Competitive Intelligence Brief. https://druglandscape.com/ci/symclosene. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing